NCT01500122已完成1 期
An Open-label, Non Randomized Monocentric Phase I Study Evaluation the Pharmacokinetic Profile of Novel Formulations of RHUDEX®
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- MediGene
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- PK blood samples
研究概览
简要总结
The primary objectives of the study are:
- To compare the pharmacokinetic profiles of RhuDex administered as two novel oral formulations
- To identify the lead formulation and optimise the pharmacokinetic profile by modifying the quantitative composition of that formulation
- Optional: To assess the intravenous pharmacokinetics of RhuDex following administration of an IV microtracer of [14C]RhuDex
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males;
- •Age 18-45 years;
- •Body weight between 70-80 kg;
- •Body Mass Index (BMI) of 18-25 kg/m2;
- •Subject must agree to use an adequate method of contraception (as defined in section 9.4);
- •Must provide written informed consent;
- •Non-smokers (subjects who have never smoked);
- •Absence of cardiovascular risk factors at screening including 12-lead standard ECG, acceptable clinical laboratory tests and the following laboratory parameters within acceptable range: CK; LDH; GPT/GOT (ALAT/ASAT); y-GT, total vs. unconjugated/conjugated serum bilirubin; serum creatinine as judged by the Investigator
- •Must be willing and able to communicate and participate in the whole study.
排除标准
- •Participation in a clinical research study within the previous 3 months;
- •Subjects who have previously been enrolled in this study;
- •History of any drug or alcohol abuse in the past 2 years;
- •Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine);
- •A breath carbon monoxide reading of greater than 10 ppm at screening;
- •Radiation exposure from clinical studies, including that from the present study, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 mSv in the last twelve months or 10 mSv in the last five years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study;
- •Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the Investigator (Section 20);
- •Positive drugs of abuse test result (Section 20);
- •Positive HBV, HCV or HIV results;
- •History of cardiovascular disease,
- •History of sudden death or cardiovascular death before the age of 50 in any first degree relative;
- •History of clinically significant renal, hepatic, respiratory and particularly gastrointestinal disease, especially peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's Disease or Irritable Bowel Syndrome;
- •Any chronic infections e.g. TB
- •Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients;
- •Presence or history of allergy requiring treatment. Hayfever is allowed unless it is active;
- •Donation or loss of greater than 400 mL of blood within the previous three months;
- •Subjects receiving prohibited medication as described in Section 9.5;
- •Subjects having received any of the following medication on a regular basis within the previous 3 months: antihypertensives such as ß-blockers, Ca-channel-inhibitors or inhibitors of the renin-angiotensin-system, statins, ASS or any other NSAIDs, diuretics, antacids/PPIs; anticoagulants, antiarrhythmics, antidepressants, antipsychotics;
- •Failure to satisfy the Investigator of fitness to participate for any other reason.
结局指标
主要结局
PK blood samples
时间窗: taken predose, 0.5 h - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8- 12- 24 -48 - 72 hours after dosing
All target PK evaluations will be made on the basis that the optimal plasma PK profile will be characterised by a plasma Cmax \< 5000 ng/mL, an elimination half-life of \> 8h and a C(last) (24h) of around 800-1000 ng/mL. Formulations will explicity not be selected based on determinations of Cmax or AUC(0-inf) alone
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.Healthy VolunteersNCT02189733Ablynx, a Sanofi company24
已完成
1 期
Study to Evaluate the Pharmacokinetics, Pharmacodynamics and SafetyHealthyPharmacokineticsPharmacodynamicsIlaprazoleNCT01820143Il-Yang Pharm. Co., Ltd.40
已完成
1 期
Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult VolunteersHealthy VolunteersNCT03856970Ironwood Pharmaceuticals, Inc.87
已完成
2 期
Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics SubjectsIntubated and Mechanically Ventilated Pediatric SubjectsNCT00652028Hospira, now a wholly owned subsidiary of Pfizer69
已完成
2 期
Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 MonthsSedationPainNCT01378988Hospira, now a wholly owned subsidiary of Pfizer5